Ortho-Clinical Diagnostic refinanced its credit agreement. The amended agreement consists of a $2.325 billion term B loan and a $350 revolving credit facility.
Proceeds from the facilities were used on the amendment effective date to refinance existing indebtedness. Proceeds from the revolver may also be used in the future for general corporate purposes.
Barclays, Goldman Sachs, Credit Suisse, UBS and Nomura were joint lead arrangers on the transaction. Cahill represented the arrangers.
Ortho-Clinical Diagnostics provides in vitro diagnostics and high-quality products and services to the global clinical laboratory and immunohematology communities.
